rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    CYBN
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Cybin Expects Key Phase III Depression Trial Results This Quarter
      Nov 10Yahoo FinanceCYBN
      Cybin Eyes Q4 Phase III Depression Data as Anxiety Program Advances
      Oct 21Yahoo FinanceCYBN
      Cybin Inc. (HELP) Upgraded to Buy: What Does It Mean for the Stock?
      Oct 20Yahoo FinanceCYBN
      Cybin Inc. (HELP-NE) Insider Trade Summaries

      The latest insider stock transactions for Cybin Inc. (HELP.NE).

      Oct 3The Globe and MailCYBN
      Cybin rebrands to Helus Pharma, ticker symbol unchanged
      Oct 1Investing.comCYBN
      Helus Pharma Announces Completion of Legal Name Change

      NEW YORK and TORONTO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the Company’s legal name has been changed from “Cybin Inc.” to “Helus Pharma Inc.” effective October 1, 2026. The name change was approved by shareholders at the Company’s annual and special meeting of shareholders held on Se

      Oct 1Yahoo FinanceCYBN
      Cybin Changes Legal Name to Helus Pharma
      Oct 1Yahoo FinanceCYBN
      Cybin (HELP) Stock May Be Trading At A Premium Despite Fresh Depression Trial Data
      Sep 25Yahoo FinanceCYBN
      Cybin (HELP) Shares Moved, What Is Behind The Fresh Attention?

      Cybin (NasdaqGM:HELP), which is rebranding as Helus Pharma, has just wrapped up a pivotal shareholder meeting approving a legal name change and confirming its full director slate for the coming year. For investors tracking Cybin, the legal rebrand to Helus Pharma comes after a sharp run in the share price over recent months. The 90 day share price return is 116.28% and the 1 year total shareholder return is 115.56%. In contrast, the 3 year total shareholder return is down 37.40% and the 5...

      Sep 24Yahoo FinanceCYBN
      Helus Pharma Eyes Q4 Phase III Data for HLP-003 in Major Depression

      Helus Pharma, formerly known as Cybin (NASDAQ:HELP), outlined its late-stage development plans for HLP-003 in adjunctive major depressive disorder (MDD) and discussed its broader pipeline of serotonergic agonists during TD Cowen’s Novel Mechanisms in Neuropsychiatry virtual summit. Michael Halstead

      Sep 24Yahoo FinanceCYBN
      Helus Pharma shareholders approve name change from Cybin Inc.
      Sep 22Investing.comCYBN
      Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change

      TORONTO, Sept. 22, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (“Helus” or the “Company”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), is pleased to announce the voting results for each of the matters presented at the Company’s annual and special meeting of shareholders held on September 22, 2026 (the “Meeting”). There were 107 shareholders represented in person or by proxy at the Meeting hol

      Sep 22Yahoo FinanceCYBN
      Cybin Shareholders Weigh Helus Pharma Rebrand, Eight-Member Board

      Cybin (NASDAQ:HELP), doing business as Helus Pharma, held its Annual General and Special Meeting of Shareholders, where shareholders were asked to consider resolutions related to the company’s auditor, board size, corporate name and director elections. Eric So, the company’s co-founder and executiv

      Sep 22Yahoo FinanceCYBN
      Cybin Insider Bought Shares Worth $1,347,050, According to a Recent SEC Filing
      Sep 21Yahoo FinanceCYBN
      Cybin Eyes Q4 Phase 3 Data for Depression Drug HLP003

      Cybin (NASDAQ:HELP) executives outlined plans for its late-stage depression program, including an expected fourth-quarter Phase 3 data readout for HLP003, during H.C. Wainwright’s 28th Annual Global Investment Conference. The company, referred to in the presentation as Helus Pharma, is developing se

      Sep 21Yahoo FinanceCYBN
      Cybin Eyes Q4 Phase III Depression Readout as Psychedelic Pipeline Advances

      Helus Pharma Chief Executive Officer Michael Halstead said the company expects a pivotal Phase III readout for its HLP003 program in adjunctive major depressive disorder in the fourth quarter, describing the data as a key near-term catalyst for the company’s mental health treatment pipeline. Speaki

      Sep 21Yahoo FinanceCYBN
      Cybin Insider Bought Shares Worth $1,238,670, According to a Recent SEC Filing
      Sep 11Yahoo FinanceCYBN
      Cybin Insider Bought Shares Worth $1,247,190, According to a Recent SEC Filing
      Sep 11Yahoo FinanceCYBN
      Cybin Insider Bought Shares Worth $1,208,900, According to a Recent SEC Filing

      Eric H. So L., Director, Executive Chair, on September 04, 2026, executed a purchase for 100,000 sha

      Sep 10Yahoo FinanceCYBN
      Cybin Insider Bought Shares Worth $1,178,280, According to a Recent SEC Filing
      Sep 10Yahoo FinanceCYBN
      Cybin Insider Bought Shares Worth $1,042,677, According to a Recent SEC Filing
      Sep 9Yahoo FinanceCYBN
      Cybin Insider Bought Shares Worth $1,121,475, According to a Recent SEC Filing
      Sep 9Yahoo FinanceCYBN
      Helus Pharma to Participate at the 2026 Cantor Global Healthcare Conference in New York

      CEO Michael Halstead to participate in a fireside chat on Friday, September 11, 2026 at 8:00 a.m. EDT.NEW YORK and TORONTO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Helus Pharma (Nasdaq: HELP) (Cboe CA: HELP) (the “Company” or “Helus Pharma”), a clinical-stage pharmaceutical company committed to helping minds heal by developing novel serotonergic agonists (“NSAs”), today announced that Michael Halstead, Helus Pharma’s Chief Executive Officer, will participate in a fireside chat at the Cantor Global He

      Sep 3Yahoo FinanceCYBN
      Cybin (HELP) Gets A Fresh Look On Trial Progress And CEO Change

      Why Cybin Stock Is Back on Investors’ Radar Cybin (HELP) has attracted fresh attention after progress in its psychedelic medicine pipeline, including HLP003 advancing into a Phase 3 trial for major depressive disorder, and the appointment of Michael Halstead as CEO. Cybin’s share price has moved sharply in recent months, with a 1 month share price return of 83.53% and a 90 day share price return of 215.69%. The 1 year total shareholder return of 87.72% contrasts with a weaker 5 year total...

      Aug 26Yahoo FinanceCYBN
      Cybin (CYBN) Stock Sees Fair Value Lift As Sector Research Supports Growth Assumptions

      Cybin’s fair value estimate has moved from US$37.57 to US$41.62 per share, an adjustment of about 11% in the latest analyst model. Recent sector research on psychedelic neuropsychiatry stocks, along with updates around peers’ late stage programs and regulatory tone, is helping shape how analysts frame this higher fair value range for Cybin. Read on to see how these shifting assumptions and new data points can help you track the evolving narrative around the stock. Stay updated as the Fair...

      Aug 22Yahoo FinanceCYBN
      Helus Pharma: An Undervalued Psychedelic Platform Approaching A Major Catalyst
      Aug 21Seeking AlphaCYBN

      This is the newest page. Registered accounts read further back.